Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Biomed Pharmacother ; 81: 416-423, 2016 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-27261621

RESUMEN

UNLABELLED: The increasing evidence suggesting the role of free radicals in bone resorption and bone loss prompted us to explore whether the consumption of antioxidant rich medicinal plant C. quadrangularis modifies antioxidant status in ovariectomized rats. METHODS: Twenty four female adult rats, 90days old showing regular estrous cycles were used for the present study. The animals were divided into two groups. The Group-1 rats (n=6) were sham operated and Group-II rats were bilaterally ovariectomized (n=18) and treated with C. quadrangularis for sixty days (100mg/kg body weight and 250mg/kg body weight). After sixty days, the rats were killed, femora were dissected out, minced and homogenized in Tris-HCl buffer (pH 7.4) and the supernatant was collected and used for biochemical assays. RESULTS: Ovariectomy registered a decrease (p<0.05) in the activities of SOD, GPx, GST, ALP, collagen content and increased (p<0.05) the activities of TRAP and lipid peroxidation. Simultaneous administration of C. quadrangularis maintained the enzyme activities in ovariectomized rats. CONCLUSION: C. quadrangularis, a natural herb may be used to treat the estrogen deficiency/menopause onset and ovariectomy induced oxidative stress.


Asunto(s)
Cissus/química , Fémur/efectos de los fármacos , Fémur/patología , Ovariectomía/efectos adversos , Estrés Oxidativo/efectos de los fármacos , Extractos Vegetales/farmacología , Envejecimiento , Fosfatasa Alcalina/metabolismo , Animales , Colágeno/metabolismo , Femenino , Fémur/enzimología , Glutatión Peroxidasa/metabolismo , Glutatión Transferasa/metabolismo , Peróxido de Hidrógeno/metabolismo , Peroxidación de Lípido/efectos de los fármacos , Ratas Wistar , Superóxido Dismutasa/metabolismo , Fosfatasa Ácida Tartratorresistente/metabolismo
2.
Pharmacogn Mag ; 8(32): 285-91, 2012 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-24082632

RESUMEN

BACKGROUND: Antioxidant properties of Crataeva nurvala bark contains a variety of the bioactive phytochemical constituents in medicinal plants which include flavonoids, phenolic compounds, tannins, anthracene derivatives, and essential oils. Components from Crataeva nurvala bark have been accounted to play an important role in scavenging free radicals generated by mutagens and carcinogens. Androgens are the key factors in either the initiation or progression of prostate cancer by inducing oxidative stress. In the present set of investigations, the antioxidative potential of Crataeva nurvala bark extract against androgen-mediated oxidative stress in male Wistar rats has been studied. MATERIALS AND METHODS: Oxidative damage in prostate was induced in rats by the injection of testosterone (100 mg/kg body weight [bw]) for 3 days followed by injection of chemical carcinogen N-Methyl N-Nitroso Urea (50 mg/kg bw) for 1 week. The oxidative damage in prostate-induced rats were treated with the ethanolic extract of Crataeva nurvala bark (150 mg/kg bw) and testosterone injection (2 mg/ kg bw) was also continued through the experimental period of 4 months. The prostate tissue was dissected out for biochemical analysis of lipid peroxidation and enzymic-antioxidants viz. catalase, superoxide dismutase, glutathione peroxidase, glutathione-S-transferase, and glutathione reductase; the non-enzymic antioxidants viz. reduced glutathione, and Vitamin C. RESULTS: The results revealed that testosterone administration induced the oxidative stress in rat prostate; however, in drug (150 mg/kg bw) supplemented groups, a significant protective effect of Crataeva nurvala bark against testosterone-induced oxidative injury was recorded. CONCLUSION: Hence, the study reveals that constituents present in Crataeva nurvala bark impart protection against androgen-induced oxidative injury in prostate.

3.
Mol Cell Biochem ; 305(1-2): 113-21, 2007 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-17636461

RESUMEN

Development of oral cancer is clearly linked to the usage of smokeless tobacco. The molecular mechanisms involved in this process are however not well understood. Toward this goal, we investigated the effect of smokeless tobacco exposure on apoptosis of oral epithelial cells. Exposure of oral epithelial cells to smokeless tobacco extract (STE) induces apoptosis in a dose-dependent manner, until a threshold level of nicotine is achieved upon which apoptosis is inhibited. 1 mM of nicotine is able to inhibit apoptosis significantly induced by STE in these oral cells. Exposure of cells to nicotine alone has no effect on apoptosis, but nicotine inhibits apoptosis induced by other agents present in STE. In this study we show that, the anti-apoptotic action of nicotine is specifically associated with down-regulation of nitric oxide (NO) production. Using specific inducers of NO, we have demonstrated that inhibition of apoptosis by nicotine is through down-regulation of NO production. Further, we observed that nicotine clearly acts as a sink of NO radicals, shown using peroxynitrite generator (SIN-1) in conjunction or absence of radical scavengers. Nicotine thus causes most damage in transformed epithelial cells as depicted by accumulation of nitrotyrosine in a 3-NT ELISA assay. Inhibition of apoptosis is a hallmark in tumor progression and propels development of cancer. It may further result in functional loss of apoptotic effector mechanisms in the transformed cells. Thus, our data clearly indicates that inhibition of NO-induced apoptosis by nicotine may lead to tobacco-induced oral carcinogenesis, and implies careful development of modalities in tobacco cessation programs.


Asunto(s)
Apoptosis/efectos de los fármacos , Células Epiteliales/efectos de los fármacos , Mucosa Bucal/efectos de los fármacos , Nicotina/toxicidad , Óxido Nítrico/antagonistas & inhibidores , Animales , Carcinoma/inducido químicamente , Carcinoma/metabolismo , Carcinoma/patología , Cricetinae , Relación Dosis-Respuesta a Droga , Mesocricetus , Neoplasias de la Boca/inducido químicamente , Neoplasias de la Boca/metabolismo , Neoplasias de la Boca/patología , Óxido Nítrico/metabolismo , Óxido Nítrico/fisiología , Estrés Oxidativo/efectos de los fármacos , Ácido Peroxinitroso/metabolismo , Tabaco sin Humo/toxicidad , Células Tumorales Cultivadas
4.
BMC Urol ; 5: 5, 2005 Mar 24.
Artículo en Inglés | MEDLINE | ID: mdl-15790403

RESUMEN

BACKGROUND: The changes in gene expression profile as prostate cancer progresses from an androgen-dependent disease to an androgen-independent disease are still largely unknown. METHODS: We examined the gene expression profile in the LNCaP prostate cancer progression model during chronic treatment with Casodex using cDNA microarrays consisting of 2305 randomly chosen genes. RESULTS: Our studies revealed a representative collection of genes whose expression was differentially regulated in LNCaP cells upon treatment with Casodex. A set of 15 genes were shown to be highly expressed in Casodex-treated LNCaP cells compared to the reference sample. This set of highly expressed genes represents a signature collection unique to prostate cancer since their expression was significantly greater than that of the collective pool of ten cancer cell lines of the reference sample. The highly expressed signature collection included the hypoxia-related genes membrane metallo-endopeptidase (MME), cyclin G2, and Bcl2/adenovirus E1B 19 kDa (BNIP3). Given the roles of these genes in angiogenesis, cell cycle regulation, and apoptosis, we further analyzed their expression and concluded that these genes may be involved in the molecular changes that lead to androgen-independence in prostate cancer. CONCLUSION: Our data indicate that one of the mechanisms of Casodex action in prostate cancer cells is induction of hypoxic gene expression.


Asunto(s)
Anilidas/uso terapéutico , Antineoplásicos/uso terapéutico , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Neoplasias de la Próstata/tratamiento farmacológico , Neoplasias de la Próstata/genética , Hipoxia de la Célula/efectos de los fármacos , Línea Celular Tumoral , Progresión de la Enfermedad , Humanos , Masculino , Nitrilos , Compuestos de Tosilo
5.
BMC Cancer ; 4: 8, 2004 Mar 08.
Artículo en Inglés | MEDLINE | ID: mdl-15070421

RESUMEN

BACKGROUND: Annexin I, one of the 20 members of the annexin family of calcium and phospholipid-binding proteins, has been implicated in diverse biological processes including signal transduction, mediation of apoptosis and immunosuppression. Previous studies have shown increased annexin I expression in pancreatic and breast cancers, while it is absent in prostate and esophageal cancers. RESULTS: Data presented here show that annexin I mRNA and protein are undetectable in 10 out of 12 B-cell lymphoma cell lines examined. Southern blot analysis indicates that the annexin I gene is intact in B-cell lymphoma cell lines. Aberrant methylation was examined as a cause for lack of annexin I expression by treating cells 5-Aza-2-deoxycytidine. Reexpression of annexin I was observed after prolonged treatment with the demethylating agent indicating methylation may be one of the mechanisms of annexin I silencing. Treatment of Raji and OMA-BL-1 cells with lipopolysaccharide, an inflammation inducer, and with hydrogen peroxide, a promoter of oxidative stress, also failed to induce annexin I expression. Annexin I expression was examined in primary lymphoma tissues by immunohistochemistry and presence of annexin I in a subset of normal B-cells and absence of annexin I expression in the lymphoma tissues were observed. These results show that annexin I is expressed in normal B-cells, and its expression is lost in all primary B-cell lymphomas and 10 of 12 B-cell lymphoma cell lines. CONCLUSIONS: Our results suggest that, similar to prostate and esophageal cancers, annexin I may be an endogenous suppressor of cancer development, and loss of annexin I may contribute to B-cell lymphoma development.


Asunto(s)
Anexina A1/metabolismo , Linfoma de Células B/metabolismo , Proteínas de Neoplasias/metabolismo , Anexina A1/genética , Línea Celular Tumoral/metabolismo , Metilación de ADN , Humanos , Peróxido de Hidrógeno/farmacología , Lipopolisacáridos/farmacología , Proteínas de Neoplasias/genética , ARN Mensajero/metabolismo
6.
Mol Cancer ; 2: 34, 2003 Oct 08.
Artículo en Inglés | MEDLINE | ID: mdl-14613585

RESUMEN

BACKGROUND: Prostate cancer (PCa) incidences vary with genetic, geographical and ethnic dietary background of patients while angiogenesis is modulated through exquisite interplay of tumor-stromal interactions of biological macromolecules. We hypothesized that comprehensive analysis of four biomarkers modulating angiogenesis in PCa progression in two diverse populations might explain the variance in the incidence rates. RESULTS: Immunohistochemical analysis of 42 PCa biopsies reveals that though Anx-II expression is lost in both the Indian and American population with Gleason scores (GS) ranging between 6 and 10, up to 25 % of cells in the entire high grade (GS > 8) PD PCa samples from US show intense focal membrane staining for Anx-II unlike similarly graded specimens from India. Consistent with this observation, the prostate cancer cell lines PC-3, DU-145 and MDA PCa 2A, but not LNCaP-R, LNCAP-UR or MDA PCa 2B cell lines, express Anx-II. Transcriptional reactivation of Anx-II gene with Aza-dC could not entirely account for loss of Anx-II protein in primary PCa. Cyclooxygenase-2 (COX-2) was moderately expressed in most of high grade PIN and some MD PCa and surrounding stroma. COX-2 was not expressed in PD PCa (GS approximately 7-10), while adjacent smooth muscles cells stained weakly positive. Decorin expression was observed only in high grade PIN but not in any of the prostate cancers, atrophy or BPH while stromal areas of BPH stained intensively for DCN and decreased with advancing stages of PCa. Versican expression was weak in most of the MD PCa, moderate in all of BPH, moderately focal in PD PC, weak and focal in PIN, atrophy and adjacent stroma. CONCLUSIONS: Expression of pro- and anti-angiogenic modulators changes with stage of PCa but correlates with angiogenic status. Focal membrane staining of Anx-II reappears in high grade PCa specimens only from US indicating differential expression of Anx-II. COX-2 stained stronger in American specimens compared to Indian specimens. The sequential expression of DCN and VCN in progressive stages was similar in specimens from India and USA indicating no population-based differences. The mechanistic and regulatory role of Anx-II in PCa progression warrants further investigation.


Asunto(s)
Anexina A2/metabolismo , Regulación Neoplásica de la Expresión Génica , Neovascularización Patológica , Neoplasias de la Próstata/irrigación sanguínea , Neoplasias de la Próstata/metabolismo , Anexina A2/genética , Biomarcadores/metabolismo , Biopsia , Western Blotting , Línea Celular Tumoral , Membrana Celular/metabolismo , Ciclooxigenasa 2 , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Humanos , Inmunohistoquímica , India , Isoenzimas/metabolismo , Masculino , Proteínas de la Membrana , Neovascularización Patológica/genética , Prostaglandina-Endoperóxido Sintasas/metabolismo , Neoplasias de la Próstata/enzimología , Neoplasias de la Próstata/genética , ARN Mensajero/genética , ARN Mensajero/metabolismo , Estados Unidos
7.
Pancreatology ; 3(4): 293-302, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-12890991

RESUMEN

The human FHIT gene is altered or lost in many cancers and FHIT has been shown to be a tumor suppressor. However, the mechanism of tumor suppression by the FHIT gene remains unclear. FHIT expression is lost in primary pancreatic cancer and human pancreatic cancer cell lines. To gain insight into the function of FHIT gene, we replaced the FHIT gene in a FHIT-null pancreatic cancer cell line, and established stable fhit-expressing clones. Expression of the exogenous fhit was at similar levels as in other cultured cell lines and fhit protein was found predominantly associated with perinuclear area. fhit replacement resulted in reduced cell proliferation in transfected Panc-1 cells. Cell cycle distribution analysis indicated increased accumulation of G(0)/G(1) phase cells in transfected clones indicating a retardation of cell cycle progression. We observed specific up-regulation of cdc2 and cyclin D3 upon fhit replacement. Furthermore, Bcl-2 family members Bad, Bak, and Bcl-xS protein levels were increased in FHIT transfected clones when compared with Panc-1 cells. Multiplex RT-PCR of apoptosis pathway related genes revealed that Bcl-2 is absent and Bcl- xS message increases in FHIT transfected clones. Our data suggested that exogenous expression of FHIT in Panc-1 cells affects genes regulating cell cycle arrest and apoptosis, and these molecular changes may contribute to the tumor suppressor activity of the FHIT gene.


Asunto(s)
Ácido Anhídrido Hidrolasas , Apoptosis/genética , Proteínas de Neoplasias/genética , Neoplasias Pancreáticas/genética , Neoplasias Pancreáticas/patología , Western Blotting , Proteínas de Ciclo Celular/biosíntesis , Proteínas de Ciclo Celular/genética , Línea Celular Tumoral , Citometría de Flujo , Fase G1/genética , Terapia Genética , Humanos , Inmunohistoquímica , Microscopía Confocal , Neoplasias Pancreáticas/terapia , Fase de Descanso del Ciclo Celular/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Sales de Tetrazolio , Tiazoles , Transfección
8.
Mol Cancer Ther ; 1(14): 1265-71, 2002 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-12516959

RESUMEN

Establishment of an early and reliable biomarker for oral carcinogenesis whose expression can be monitored through noninvasive techniques will enable early diagnosis of cancer. Cyclooxygenases (COXs) have been implicated previously in several human malignancies, and the therapeutic benefit of specific COX-2 inhibitors has been elucidated. The expression of COX-2 and subsequent markers of malignant progression was studied in archival human specimens representing premalignant and malignant stages of oral cancer. We find that changes in COX-2 gene expression precede changes in expression of biomarkers related to apoptosis and angiogenesis in oral premalignant tissues as a veritable phenotype. We also report for the first time COX-2 mRNA variants in dysplastic samples and in a human papillomavirus-transformed cell line HOK-16B, indicating a possible stabilization of COX-2 message by human papillomavirus infection as an early event in oral cancer. Expression of other markers of tumor progression related to apoptosis and angiogenesis pathway genes shows relatively low level of changes in oral premalignant tissue. However, a determinant shift toward decrease in antitumor immunity was observed by cytokine gene expression profile changes.


Asunto(s)
Regulación Enzimológica de la Expresión Génica , Isoenzimas/biosíntesis , Neoplasias de la Boca/enzimología , Lesiones Precancerosas/enzimología , Prostaglandina-Endoperóxido Sintasas/biosíntesis , Secuencia de Bases , Biomarcadores de Tumor/metabolismo , Línea Celular Transformada , Ciclooxigenasa 2 , Citocinas/biosíntesis , Progresión de la Enfermedad , Humanos , Inmunohistoquímica , Proteínas de la Membrana , Datos de Secuencia Molecular , Fenotipo , Reacción en Cadena de la Polimerasa , ARN Mensajero/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA